The results of multivariate analysis of time to engraftment and GVHD
. | Bone marrow transplantation, n = 45 . | Cord blood transplantation, n = 68 . | Hazard ratio (95% CI)* . | P . |
|---|---|---|---|---|
| Absolute neutrophil count greater than 0.5 × 109/L | 0.18 (0.11-0.30) | < .01 | ||
| No. of patients to achieve (%) | 45 (100) | 60 (88) | ||
| Median | 18 | 22 | ||
| Range | 12-33 | 16-41 | ||
| Platelet count greater than 20 × 109/L | 0.48 (0.29-0.81) | < .01 | ||
| No. of patients to achieve (%) | 42 (93) | 55 (81) | ||
| Median | 25 | 40 | ||
| Range | 10-172 | 13-99 | ||
| Platelet count greater than 50 × 109/L | 0.44 (0.28-0.69) | < .01 | ||
| No. of patients to achieve (%) | 38 (84) | 55 (81) | ||
| Median | 28 | 48 | ||
| Range | 16-113 | 30-263 | ||
| Acute GVHD | ||||
| No. of evaluable patients† | 45 | 60 | ||
| Grade no. (%) | ||||
| 0 | 6 (13) | 5 (8) | ||
| I | 9 (20) | 25 (42) | ||
| II | 18 (40) | 26 (43) | ||
| III | 2 (4) | 3 (5) | ||
| IV | 10 (22) | 1 (2) | ||
| II-IV | 30 | 30 | 0.61 (0.37-1.01) | .05 |
| III-IV | 12 | 4 | 0.09 (0.01-0.58) | .01 |
| Requiring steroid therapy for acute GVHD | ||||
| Patients treated with steroid | 21 | 13 | 0.33 (0.16-0.65) | < .01 |
| Chronic GVHD | ||||
| No. of evaluable patients‡ | 35 | 54 | ||
| Limited + extensive | 26 | 42 | 0.67 (0.35-1.26) | .21 |
| Extensive | 14 | 13 | 0.60 (0.28-1.28) | .18 |
. | Bone marrow transplantation, n = 45 . | Cord blood transplantation, n = 68 . | Hazard ratio (95% CI)* . | P . |
|---|---|---|---|---|
| Absolute neutrophil count greater than 0.5 × 109/L | 0.18 (0.11-0.30) | < .01 | ||
| No. of patients to achieve (%) | 45 (100) | 60 (88) | ||
| Median | 18 | 22 | ||
| Range | 12-33 | 16-41 | ||
| Platelet count greater than 20 × 109/L | 0.48 (0.29-0.81) | < .01 | ||
| No. of patients to achieve (%) | 42 (93) | 55 (81) | ||
| Median | 25 | 40 | ||
| Range | 10-172 | 13-99 | ||
| Platelet count greater than 50 × 109/L | 0.44 (0.28-0.69) | < .01 | ||
| No. of patients to achieve (%) | 38 (84) | 55 (81) | ||
| Median | 28 | 48 | ||
| Range | 16-113 | 30-263 | ||
| Acute GVHD | ||||
| No. of evaluable patients† | 45 | 60 | ||
| Grade no. (%) | ||||
| 0 | 6 (13) | 5 (8) | ||
| I | 9 (20) | 25 (42) | ||
| II | 18 (40) | 26 (43) | ||
| III | 2 (4) | 3 (5) | ||
| IV | 10 (22) | 1 (2) | ||
| II-IV | 30 | 30 | 0.61 (0.37-1.01) | .05 |
| III-IV | 12 | 4 | 0.09 (0.01-0.58) | .01 |
| Requiring steroid therapy for acute GVHD | ||||
| Patients treated with steroid | 21 | 13 | 0.33 (0.16-0.65) | < .01 |
| Chronic GVHD | ||||
| No. of evaluable patients‡ | 35 | 54 | ||
| Limited + extensive | 26 | 42 | 0.67 (0.35-1.26) | .21 |
| Extensive | 14 | 13 | 0.60 (0.28-1.28) | .18 |
CI indicates confidence interval; GVHD, graft-versus-host disease.
The hazard ratio is for cord blood transplantation compared with bone marrow transplantation
Acute GVHD was evaluated in patients surviving 21 days or longer after transplantation with evidence of engraftment
Chronic GVHD disease was evaluated in patients surviving 100 days or longer after transplantation with engraftment